CN110859852A - 一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物及其制备方法 - Google Patents
一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物及其制备方法 Download PDFInfo
- Publication number
- CN110859852A CN110859852A CN201911145239.7A CN201911145239A CN110859852A CN 110859852 A CN110859852 A CN 110859852A CN 201911145239 A CN201911145239 A CN 201911145239A CN 110859852 A CN110859852 A CN 110859852A
- Authority
- CN
- China
- Prior art keywords
- triamcinolone acetonide
- platelet
- rich plasma
- injection
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002117 triamcinolone acetonide Drugs 0.000 title claims abstract description 65
- 210000004623 platelet-rich plasma Anatomy 0.000 title claims abstract description 56
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 title claims abstract description 53
- 150000001875 compounds Chemical class 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 201000010099 disease Diseases 0.000 title claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 14
- 239000007924 injection Substances 0.000 claims abstract description 43
- 238000002347 injection Methods 0.000 claims abstract description 43
- 238000005303 weighing Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 239000000835 fiber Substances 0.000 description 9
- 210000002435 tendon Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- -1 triamcinolone acetonide compound Chemical class 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种富血小板血浆联合曲安奈德注射液复合物及其制备方法，该复合物包括体积质量比（ml/mg）为2‑6:10‑40的富血小板血浆和曲安奈德注射液。本发明的复合物可使药物的作用明显增强、炎症反应明显降低，简单易行、见效迅速、有效率高、副作用低。
Description
技术领域
本发明属于康复医疗美容技术领域，具体地说，涉及一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物及其制备方法。
背景技术
富血小板血浆，英语Platelet-Rich Plasma，缩写为PRP，富含有9大类生长因子，如血小板衍生生长因子（PDGF），转化生长因子-β(TGF-β)，类胰岛素生长因子（IGF），表皮生长因子（EGF），血管内皮生长因子（VEGF）等。通过血液提取PRP后，经过激活，PRP可以快速释放出生长因子，被细胞及组织摄取直接吸收利用，修复损伤；可以抑制炎症因子表达，提高抗炎因子表达，缓解局部炎症反应。
PRP的来源采用的是自体血分离，没有免疫排斥，生物安全性高几乎没有副作用，且效果持续持久。目前在皮肤美容方面应用广泛，在肌腱韧带及骨关节损伤和退行性变的治疗上也有一定的进展。但由于PRP在制备的过程中，或多或少会有白细胞残留，注射后白细胞会参与炎症反应，释放IL-6等炎症介质，增加局部炎症反应的风险，影响和破坏胶原蛋白产生，进而导致损伤修复受阻。
曲安奈德为曲安奈德A的醋酸酯衍生物，是中效糖皮质激素，作用与曲安西龙相似，具有抗炎、抗瘙痒和收缩血管等作用，水钠潴留作用微弱，其抗炎和抗过敏作用较强而持久，效力比可的松大20～30倍，且局部使用时的耐受性较好。对疼痛、关节肿胀、僵直（这些症状是创伤、风湿性关节炎、骨关节炎、滑膜炎、粘液囊炎、腱炎的典型症状）给予有效的局部、短期治疗。
因此，如何防止PRP中白细胞的促炎作用成为了本领域需要克服的技术困难。
发明内容
有鉴于此，本发明针对上述的问题，提供了一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物及其制备方法。
为了解决上述技术问题，本发明公开了一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物，包括体积质量比（ml/mg）为2-6:10-40的富血小板血浆和曲安奈德注射液。
可选地，包括体积质量比（ml/mg）为4:20的富血小板血浆和曲安奈德注射液。
本发明还公开了一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物的制备方法，包括以下步骤：
步骤1、称量体积质量比（ml/mg）为2-6:10-40的富血小板血浆和曲安奈德注射液；
步骤2、将富血小板血浆和曲安奈德注射液混合，制备得到富血小板血浆联合曲安奈德注射液复合物。
与现有技术相比，本发明可以获得包括以下技术效果：
在本发明的曲安奈德含量范围内可以抑制PRP中白细胞导致的炎症反应并减少诱导产生促炎相关细胞因子，降低IL-6等促炎因子产生，有效控制炎症反应，从而促使多种胶原蛋白合成，损伤修复愈合。
附图说明
图1是本发明注射治疗后4周肌腱组织中的IL-6含量的对比图；
图2是本发明注射治疗4周后肌腱组织中I型胶原纤维（Col1）和III型胶原纤维(Col3)表达水平的统计的对比图；
图3是本发明注射不同比例PRP-曲安奈德复合物4周后肌腱组织中的IL-6含量的对比图；
图4是本发明注射不同比例PRP-曲安奈德复合物4周后肌腱组织中I型胶原纤维（Col1）和III型胶原纤维(Col3)表达水平的统计的对比图；
具体实施方式
以下将配合实施例来详细说明本发明的实施方式，藉此对本发明如何应用技术手段来解决技术问题并达成技术功效的实现过程能充分理解并据以实施。
本发明公开了一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物，包括体积质量比（ml/mg）为2-6:10-40的富血小板血浆和曲安奈德注射液。
其中，富血小板血浆为市售，也可以为患者自体血提取、曲安奈德注射液为昆明积大制药股份有限公司生产。
本发明还公开了一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物的制备方法，包括以下步骤：
步骤1、称量：称量体积质量比（ml/mg）为2-6:10-40的富血小板血浆和曲安奈德注射液；
步骤2、将富血小板血浆和曲安奈德注射液混合，制备得到富血小板血浆联合曲安奈德注射液复合物。
参见下述的具体实施例：
实施例1
用于劳损性疾病的富血小板血浆联合曲安奈德复合物，包括体积质量比（ml/mg）为4:20的富血小板血浆和曲安奈德注射液，优选为富血小板血浆4ml，曲安奈德注射液20mg。
其制备方法为：按照上述称量富血小板血浆和曲安奈德注射液；将富血小板血浆和曲安奈德注射液混合，制备得到富血小板血浆联合曲安奈德注射液复合物。
实施例2
用于劳损性疾病的富血小板血浆联合曲安奈德复合物，包括体积质量比（ml/mg）为2:40的富血小板血浆和曲安奈德注射液，优选为富血小板血浆2ml，曲安奈德注射液40mg。
其制备方法为：按照上述称量富血小板血浆和曲安奈德注射液；将富血小板血浆和曲安奈德注射液混合，制备得到富血小板血浆联合曲安奈德注射液复合物。
实施例3
用于劳损性疾病的富血小板血浆联合曲安奈德复合物，包括体积质量比（ml/mg）为6:10的富血小板血浆和曲安奈德注射液，优选为富血小板血浆6ml，曲安奈德注射液10mg。
其制备方法为：按照上述称量富血小板血浆和曲安奈德注射液；将富血小板血浆和曲安奈德注射液混合，制备得到富血小板血浆联合曲安奈德注射液复合物。
下面结合具体的实验数据来说明本发明的技术效果：
1、将生理盐水（Saline）、富血小板血浆以及上述实施例1制备得到的富血小板血浆联合曲安奈德注射液复合物用于降低IL-6的研究：
实验结果见图1、3，图1中PRP-曲安奈德复合物组IL-6的含量显著低于PRP组和对照组，且对照组和PRP组之间IL-6含量没有明显差异。说明PRP-曲安奈德复合物能有效的降低炎症表达。图3中PRP-曲安奈德复合物4:20（ml/mg）组和2:40（ml/mg）组IL-6的含量显著低于6:10（ml/mg）组，且4:20（ml/mg）和2:40（ml/mg）组之间IL-6含量没有明显差异。说明PRP-曲安奈德复合物4:20（ml/mg）和2:40（ml/mg）的配比能更有效的降低炎症表达。
由图1、3可知，本发明实施例1制备得到的富血小板血浆联合曲安奈德注射液复合物与生理盐水（Saline）、富血小板血浆相比，对降低IL-6促炎因子具有显著的效果，因此，本发明的富血小板血浆联合曲安奈德注射液复合物具有减少促炎因子产生的效果。
将生理盐水（Saline）、富血小板血浆以及上述实施例1制备得到的富血小板血浆联合曲安奈德注射液复合物用于提高胶原纤维I和胶原纤维III表达的研究：
实验结果见图2、4，图2中PRP-曲安奈德复合物组Col1和Col3的比值显著高于PRP组和对照组，且对照组和PRP组之间Col1和Col3的比值没有明显差异。说明PRP-曲安奈德复合物能有效的提高胶原纤维的表达，促进腱组织修复。图4中PRP-曲安奈德复合物4:20（ml/mg）组Col1和Col3的比值显著高于2:40（ml/mg）组和6:10（ml/mg）组，且2:40（ml/mg）组和6:10（ml/mg）组之间Col1和Col3的比值没有明显差异。说明PRP-曲安奈德复合物4:20（ml/mg）的配比能更有效的提高胶原纤维的表达，促进腱组织修复。
由图2、4可知，本发明实施例1制备得到的富血小板血浆联合曲安奈德注射液复合物与生理盐水（Saline）、富血小板血浆相比，对提高胶原纤维I和胶原纤维III表达具有显著的效果。因此，本发明的富血小板血浆联合曲安奈德注射液复合物具有提高胶原纤维表达，促进腱组织修复的效果。
通过腧穴—经络—脏腑注射本发明制备得到的复合物，药效得以几何式的放大。实践证明，富血小板血浆和曲安奈德复合物配伍，可使药物的作用明显增强，由于它简单易行、见效迅速、有效率高，能够用于治疗劳损性疾病。
上述说明示出并描述了发明的若干优选实施例，但如前所述，应当理解发明并非局限于本文所披露的形式，不应看作是对其他实施例的排除，而可用于各种其他组合、修改和环境，并能够在本文所述发明构想范围内，通过上述教导或相关领域的技术或知识进行改动。而本领域人员所进行的改动和变化不脱离发明的精神和范围，则都应在发明所附权利要求的保护范围内。
Claims (3)
1.一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物，其特征在于，包括体积质量比（ml/mg）为2-6:10-40的富血小板血浆和曲安奈德注射液。
2.根据权利要求1所述的复合物，其特征在于，包括体积质量比（ml/mg）为4:20的富血小板血浆和曲安奈德注射液。
3.一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物的制备方法，其特征在于，包括以下步骤：
步骤1、称量体积质量比（ml/mg）为2-6:10-40的富血小板血浆和曲安奈德注射液；
步骤2、将富血小板血浆和曲安奈德注射液混合，制备得到富血小板血浆联合曲安奈德注射液复合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911145239.7A CN110859852A (zh) | 2019-11-21 | 2019-11-21 | 一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911145239.7A CN110859852A (zh) | 2019-11-21 | 2019-11-21 | 一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110859852A true CN110859852A (zh) | 2020-03-06 |
Family
ID=69655120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911145239.7A Pending CN110859852A (zh) | 2019-11-21 | 2019-11-21 | 一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110859852A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120195938A1 (en) * | 2007-05-30 | 2012-08-02 | James Louis Rutkowski | Formulations and methods for recovery from dental surgery |
| CN105030789A (zh) * | 2015-06-24 | 2015-11-11 | 天津医科大学总医院 | 曲安奈德的新用途 |
-
2019
- 2019-11-21 CN CN201911145239.7A patent/CN110859852A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120195938A1 (en) * | 2007-05-30 | 2012-08-02 | James Louis Rutkowski | Formulations and methods for recovery from dental surgery |
| CN105030789A (zh) * | 2015-06-24 | 2015-11-11 | 天津医科大学总医院 | 曲安奈德的新用途 |
Non-Patent Citations (4)
| Title |
|---|
| CHRIS HYUNCHUL JO等: "Allogenic Pure Platelet-Rich Plasma Therapy for Rotator Cuff Disease", 《THE AMERICAN JOURNAL OF SPORTS MEDICINE》 * |
| T. MUTO等: "Effects of platelet-rich plasma and triamcinolone acetonide on interleukin-1ß-stimulated human rotator cuff-derived cells", 《BONE JOINT RESEARCH》 * |
| TOMOYUKI MUTO等: "Platelet-Rich Plasma Protects Rotator Cuff-Derived Cells from the Deleterious Effects of Triamcinolone Acetonide", 《JOURNAL OF ORTHOPAEDIC RESEARCH》 * |
| 刘步云等: "局部注射自体富血小板血浆联合运动疗法和局部注射曲安奈德治疗跟腱病的临床疗效对比", 《四川医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021201102B2 (en) | New standardizations & medical devices for the preparation of platelet rich plasma (PRP) or bone marrow centrate (BMC) alone or in combination with hyaluronic acid | |
| KR101838156B1 (ko) | 둥근잎유홍초 추출물을 유효성분으로 함유하는 상처치유용 조성물 | |
| CN109700998B (zh) | 一种复方肌肤损伤再生修复剂及其制备方法 | |
| JP2006510637A (ja) | ダイコンソウの有機抽出物およびその利用 | |
| CN110859852A (zh) | 一种用于劳损性疾病的富血小板血浆联合曲安奈德复合物及其制备方法 | |
| CN105169317A (zh) | 一种祛疤药膏的制备方法 | |
| CN113521050B (zh) | 含有大麻二酚的组合物及其在治疗全身炎症反应综合征中的用途 | |
| CN102784223A (zh) | 三黄软膏制备防治静脉炎药剂中的应用 | |
| CN105232650A (zh) | 一种治疗烫伤的药膏及其制备和使用方法 | |
| US20240123017A1 (en) | Use of Bletilla formosana (Hayata) Schltr. Extract for The Manufacture of A Pharmaceutical Composition For Promoting Chronic Wound Healing | |
| CN118436752A (zh) | 一种疤痕软化和平复药剂的制备方法及使用方法 | |
| CN117617500A (zh) | 一种适用于术后恢复的功能型配方粉及其制备方法和用法 | |
| De Luca | Check for updates Orthobiologics: Background Paola De Luca, Michela Maria Taiana, and Laura de Girolamo | |
| CN117982562A (zh) | 一种用于治疗肝炎的中药组合物及应用 | |
| Kamilah et al. | Combination Therapy of Topical Antioxidant Gel and Platelet-Rich Plasma (PRP) in Pyoderma Gangrenosum Ulcer: A Case Report | |
| Enneper | CPD| | |
| CN118319980A (zh) | 一种具有皮肤再生修复作用的乌药提取物凝胶及其制备方法 | |
| WO1991011191A1 (en) | Pharmacological compositions containing extracts derived from gramineae plant family and uses thereof | |
| CN115624522A (zh) | 一种能够预防肺动脉压急性增高的载药乙醇注射液及其制备方法与应用 | |
| RU2266127C2 (ru) | Способ приготовления мази для лечения рожи | |
| WO2019038766A1 (en) | MEDICINAL PRODUCT FOR THE TREATMENT OF TROPHIC ULCERS AND WOUNDS AND BURNS OF VARIOUS ORIGIN | |
| CN108671053A (zh) | 一种用于治疗肛肠疾病的医用生物敷料栓剂 | |
| CN1810254A (zh) | 芍药苷的医药新用途 | |
| Newer et al. | Recent Concepts In Atopic Eczema | |
| CN107961241A (zh) | 曲克芦丁羟丙茶碱注射剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20211209 Address after: 610000 No. 6, unit 3, No. 23 Jixiang street, Qingyang District, Chengdu, Sichuan Applicant after: Zhang Qian Applicant after: Zou Li Applicant after: Cai Bo Applicant after: Jin Peng Applicant after: Guo Ying Applicant after: Huang Wenkang Address before: No.2 and No.3, 6th floor, building 7, No.5 Xixin Avenue, high tech Zone, Chengdu, Sichuan 610015 Applicant before: SICHUAN CHANGQINGSHU BIOTECHNOLOGY CO.,LTD. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230414 Address after: No. 11, 5th Floor, 1st Floor, South Section 4, 2nd Ring Road, High tech Zone, Chengdu, Sichuan, 610000 Applicant after: Sichuan Century Changqing Stem Cell Biotechnology Development Co.,Ltd. Address before: 610000 No. 6, unit 3, No. 23 Jixiang street, Qingyang District, Chengdu, Sichuan Applicant before: Zhang Qian Applicant before: Zou Li Applicant before: Cai Bo Applicant before: Jin Peng Applicant before: Guo Ying Applicant before: Huang Wenkang |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200306 |